“Les Groupes Pharmaceutiques Doivent: Ils Réinventer leur Modèle? ” (Pharmaceutical Croups: Do They Have to Re-invent their Business Model?)
In an article in the September 15 issue of La Tribune (France), Booz & Company Partner Matthias Bünte (Europe) argued it is imperative that pharmaceutical companies look to achieve new business models to stay competitive in the marketplace. “Because of price controls by governments and low productivity, yes, it is absolutely essential that pharmaceuticals re-invent their business models,” he said.